Monday , July 26 2021

Specialty Pharma Journal Specialty, Precision & Technology

Breaking News

FDA Approves Gavreto for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM
Natera Announces SMART Study Data for Aneuploidy and 22q Unblinded
Aimmune Agrees to be Acquired by Nestlé Health Science for $2 Billion
Twist Bioscience Announces Potent SARS-CoV-2 Neutralizing Data from COVID-19 Therapeutic Antibody Program
Final Analysis of the Observational GioTag Study: Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive NSCLC
Santhera Exercises Option to Obtain Worldwide Rights to Vamorolone in Duchenne Muscular Dystrophy and All Other Indications
FDA Approves Onureg, a New Oral Therapy, as Continued Treatment for Adults in First Remission with Acute Myeloid Leukemia
FDA Accepts Vertex’s sNDA for Trikafta, Symdeko and Kalydeco for Additional CFTR Mutations
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program

Tag Archives: Achillion Pharmaceuticals

July, 2015

8 July
Short and Sweet

A treatment timeline of 52 weeks to clear the hepatitis C virus from the body, thankfully, is a thing of the past. Today, treatment horizons continue to get shorter and shorter for hepatitis C infections, with 12 weeks currently being a very typical treatment time for most hepatitis C patients. …
Share

May, 2015

19 May
Janssen and Achillion Enter $1.1 Billion Hepatitis C Deal

Janssen Pharmaceuticals, Inc. has agreed to pay up to $1.1 billion for the rights to Achillion Pharmaceuticals’ pipeline of hepatitis C virus (HCV) assets. The company announced that it has entered into an exclusive worldwide license and collaboration arrangement with Achillion Pharmaceuticals to develop and commercialize one or more of …
Share